United States-based Fervent Pharmaceuticals of Greenville, North Carolina has added Ernest Mario, PhD to its Board of Representatives, it was reported yesterday.
Dr Mario is an experienced pharmaceutical executive and a recipient of the 2007 Remington Medal from the American Pharmacists' Association, pharmacy's highest honour. Throughout his career, he has worked in drugstore pharmacy, research, and management in several pharmaceutical companies. He was named chief executive of Glaxo in 1989. He led Glaxo's growth as it introduced five major products to the market and grew profits by 15%. He served as CEO of ALZA Corporation from 1993 until it was acquired by Johnson & Johnson in 2001. He then served as CEO of Reliant Pharmaceuticals Inc until its acquisition by GlaxoSmithKline. He is chairman of Soleno Therapeutics and a Venture Partner with Pappas Ventures in Research Triangle Park. He has served as a trustee of Rutgers University, the University of Rhode Island, and Duke University, where he was previously chairman of the Duke University Health System. Dr Mario continues to devote his time to working with several charitable organisations and sitting on the boards of pharmaceutical companies. Dr Mario is joining the company's Board of Representatives as the company's upcoming treatment for the vasomotor symptoms associated with menopause, such as hot flashes and night sweats, is in its Phase II clinical trial.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer